Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Janux Therapeutics Inc (JANX)
NASDAQ:JANX
Janux Therapeutics Inc (JANX) Stock Price & Analysis
226 Followers
JANX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$5.65 - $65.60
Previous Close$42.76
Volume415.72K
Average Volume (3M)804.07K
Market Cap
$2.22B
Enterprise Value$1.59B
Total Cash (Recent Filing)$651.76M
Total Debt (Recent Filing)$24.18M
Price to Earnings (P/E)―
Beta1.99
Next Earnings
Aug 06, 2024EPS Estimate
-$0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.22
Shares Outstanding51,850,667
10 Day Avg. Volume680,360
30 Day Avg. Volume804,067
Standard Deviation0.83
R-Squared0.05
Alpha0.11
Financial Highlights & Ratios
Price to Book (P/B)6.17
Price to Sales (P/S)262.75
Price to Cash Flow (P/CF)-53.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue218.14
Enterprise Value/Gross Profit196.65
Enterprise Value/Ebitda-29.37
Forecast
1Y Price Target
$63.60Price Target Upside44.58% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Janux Therapeutics Inc News
PremiumCompany Announcements
Janux Therapeutics Announces Board of Directors Reshuffle
Bulls Say, Bears Say
Bulls Say
Efficacy And SafetyBoth of Janux's assets, '007 (PSMAxCD3) and '008 (EGFRxCD3) have shown single agent efficacy in late line solid tumor patients, as well as a better safety profile compared to peer competitors.
Financial PerformanceThe company reported cash and cash equivalents of $652M at the end of the 1Q24, which is believed to be sufficient to run operations for the foreseeable future.
Market PositionJanux is viewed as one of the leaders in the space with Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms.
Bears Say
Competitive PositionBioAtla's efficacy data in combination with Opdivo is uncertain and the safety profile does not look clean.
Drug EffectivenessXilio's drug was discontinued due to lack of efficacy and poor safety.
Safety ConcernsJ&J's trial had four TRAEs leading to death, including interstitial lung disease and respiratory failure.
---
Ownership Overview
62.16% Insiders
17.37% Mutual Funds
7.56% Other Institutional Investors
12.91% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
JANX FAQ
What was Janux Therapeutics Inc’s price range in the past 12 months?
Janux Therapeutics Inc lowest stock price was $5.65 and its highest was $65.60 in the past 12 months.
What is Janux Therapeutics Inc’s market cap?
Currently, no data Available
When is Janux Therapeutics Inc’s upcoming earnings report date?
Janux Therapeutics Inc’s upcoming earnings report date is Aug 06, 2024 which is in 10 days.
How were Janux Therapeutics Inc’s earnings last quarter?
Janux Therapeutics Inc released its earnings results on May 07, 2024. The company reported -$0.3 earnings per share for the quarter, beating the consensus estimate of -$0.331 by $0.031.
Is Janux Therapeutics Inc overvalued?
According to Wall Street analysts Janux Therapeutics Inc’s price is currently Undervalued.
Does Janux Therapeutics Inc pay dividends?
Janux Therapeutics Inc does not currently pay dividends.
What is Janux Therapeutics Inc’s EPS estimate?
Janux Therapeutics Inc’s EPS estimate is -$0.31.
How many shares outstanding does Janux Therapeutics Inc have?
Janux Therapeutics Inc has 51,850,666 shares outstanding.
What happened to Janux Therapeutics Inc’s price movement after its last earnings report?
Janux Therapeutics Inc reported an EPS of -$0.3 in its last earnings report, beating expectations of -$0.331. Following the earnings report the stock price went down -9.967%.
Which hedge fund is a major shareholder of Janux Therapeutics Inc?
Among the largest hedge funds holding Janux Therapeutics Inc’s share is RA Capital Management. It holds Janux Therapeutics Inc’s shares valued at 345M.
---
Janux Therapeutics Inc Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$63.60 (44.58% Upside)
$63.60 (44.58% Upside)
Blogger Sentiment
Bullish
JANX Sentiment 80%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 247.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $209.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.8%
Last 30 Days ▼ 3.6%
Last 30 Days ▼ 3.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
224.18%
12-Months-Change
Fundamentals
Return on Equity
-11.50%
Trailing 12-Months
Asset Growth
95.20%
Trailing 12-Months
Company Description
Janux Therapeutics Inc
Janux Therapeutics Inc is an innovative biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to better treat patients suffering from cancer.
---
JANX Stock 12 Month Forecast
Average Price Target
$63.60
▲(44.58% Upside)
Technical Analysis
Best Analysts Covering JANX
1 Year
1 Year Success Rate
7/14 ratings generated profit
1 Year Average Return
+94.49%
reiterated a buy rating 3 months ago
Copying Swayampakula Ramakanth's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +94.49% per trade.
---